Schizophrenia Research最新文献

{"title":"Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials","authors":"Jing Tian ,&nbsp;Shimeng Dong ,&nbsp;Nobuyuki Nomura ,&nbsp;Spyridon Siafis ,&nbsp;Xiao Lin ,&nbsp;Hui Wu ,&nbsp;Mengchang Qin ,&nbsp;Hiroko Yanagimoto ,&nbsp;Johannes Schneider-Thoma ,&nbsp;Stefan Leucht","doi":"10.1016/j.schres.2024.10.016","DOIUrl":"10.1016/j.schres.2024.10.016","url":null,"abstract":"<div><h3>Background</h3><div>Blonanserin is approved for treating schizophrenia in Japan, South Korea, India, and China. We aimed to synthesize the efficacy and tolerability of blonanserin compared to other antipsychotics.</div></div><div><h3>Methods</h3><div>A systematic review and pairwise meta-analysis were conducted using the Cochrane Schizophrenia Group's study-based trial register until January 24, 2024. We included open and blinded randomized controlled trials (RCTs) involving schizophrenia patients, with studies lasting at least 3 weeks. Primary outcomes focused on overall schizophrenia symptoms using rating scales and relapse rates. Secondary outcomes included symptom subtypes, treatment response, dropout rates, quality of life, and side effects, analyzed using standardized mean difference (SMD), mean difference (MD), and risk ratio (RR) with 95 % confidence intervals (CIs). The review protocol was published in Open Science Framework (<span><span>https://osf.io/e7jfa/</span><svg><path></path></svg></span>).</div></div><div><h3>Results</h3><div>Fourteen acute-phase studies with 2697 participants compared blonanserin to olanzapine, haloperidol, risperidone, paliperidone, aripiprazole, amisulpride, and placebo. Blonanserin showed greater efficacy than placebo (SMD = −0.47, 95 % CI: −0.66 to −0.27) and similar efficacy to other antipsychotics in reducing schizophrenia overall symptoms. No data on the number of participants who experienced relapse with blonanserin was available in the single maintenance-phase study. There were also no clear differences between antipsychotics in most secondary efficacy outcomes, but blonanserin produced less prolactin and weight increase but more akathisia and tremor than risperidone, and less prolactin increase, anticholinergic and extrapyramidal side-effects than haloperidol.</div></div><div><h3>Conclusion</h3><div>Our study suggests that differences in efficacy between blonanserin and other antipsychotics are small and that blonanserin has a different tolerability profile than haloperidol and risperidone.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"274 ","pages":"Pages 360-373"},"PeriodicalIF":3.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142539006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct trajectories of psychotic-like experiences and their associations with violent behavior among 3539 young adults: A 3-year prospective cohort study","authors":"Shaoling Zhong,&nbsp;Hongling Zhou,&nbsp;Xin Yu,&nbsp;Yue Li,&nbsp;Xinhu Yang,&nbsp;Jiawen Zhang,&nbsp;Liang Zhou,&nbsp;Meng Sun","doi":"10.1016/j.schres.2024.10.012","DOIUrl":"10.1016/j.schres.2024.10.012","url":null,"abstract":"<div><h3>Background</h3><div>Violence perpetration may be linked to psychotic-like experiences (PLEs), but relevant research is limited, especially in general population. Therefore, we aimed to identify trajectories of PLEs and examine whether specific trajectories were related to violent behavior in a 3-year cohort study.</div></div><div><h3>Methods</h3><div>We developed a prospective cohort study and collected data in 2020 (T0), 2021 (T1), and 2022 (T2) in Guangzhou, China. A total of 3539 university students from two universities were included and completed self-report questionnaires to assess PLEs, violent ideation, violent threats, and violent acts. Socio-demographic and clinical factors were assessed and considered as confounding factors. We used growth mixture modeling to identify trajectories of PLEs. Associations between PLEs trajectories and violent behavior were examined using binary logistic regression.</div></div><div><h3>Results</h3><div>At T2, 162 (5.3 %) participants had violent behavior. We identified three distinct trajectories: <em>low stable</em> trajectory, <em>low increasing</em> trajectory, and <em>high decreasing</em> trajectory. The binary logistic regression models revealed that the <em>high decreasing</em> (OR: 2.46, 95%CI:1.60–3.72) group and the <em>low increasing</em> (OR: 11.7, 95%CI: 7.62–17.9) were associated with higher violent risk compared to the <em>low stable</em> group after controlling for baseline socio-demographic and clinical factors.</div></div><div><h3>Conclusion</h3><div>Our study delineated three distinct trajectories and indicated that PLEs trajectories are related to subsequent violent ideation and violent acts. The results provide crucial clarifications regarding the nature of the associations between PLEs trajectories and violence over time.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"274 ","pages":"Pages 374-380"},"PeriodicalIF":3.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142539007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Dyadic interaction in schizophrenia – A promising new avenue of investigation?","authors":"Georg Juckel","doi":"10.1016/j.schres.2024.09.031","DOIUrl":"10.1016/j.schres.2024.09.031","url":null,"abstract":"","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"274 ","pages":"Page 392"},"PeriodicalIF":3.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between auditory P300 event-related potential and suicidal thoughts and behaviors in first-episode antipsychotic-naïve patients with schizophrenia","authors":"Shaobing Li ,&nbsp;Chenghao Lu ,&nbsp;Nannan Liu ,&nbsp;Yanzhe Li ,&nbsp;Xinxu Wang ,&nbsp;Shen Li ,&nbsp;Jie Li ,&nbsp;Xiang Yang Zhang","doi":"10.1016/j.schres.2024.10.015","DOIUrl":"10.1016/j.schres.2024.10.015","url":null,"abstract":"<div><h3>Objective</h3><div>Suicidal thoughts and behaviors (STBs) are critical concern in schizophrenia (SZ). Concurrent changes in event-related potential (ERP), particularly the P300 (P3) components, have been observed in SZ patients, but the association between these changes and STBs remains unclear. This study aims to explore the relationships between P3 components and STBs in first-episode antipsychotic-naïve SZ (FEAN-SZ) patients.</div></div><div><h3>Methods</h3><div>The study included 321 FEAN-SZ patients and 146 healthy controls (HC). Sociodemographic data, clinical assessments, and ERP P3 components (N1, P3a, and P3b) were collected. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), while depressive symptoms were evaluated with the Hamilton Depression Scale (HAMD).</div></div><div><h3>Results</h3><div>Compared to HC, FEAN-SZ patients exhibited lower N1 and P3 amplitudes and longer latencies (all <em>p</em>_<em>s</em> &lt; 0.001). Patients with STBs exhibited higher scores on negative, general psychopathology, PANSS total and HAMD, decreased N1 and P3a amplitudes, as well as prolonged P3a and P3b latencies compared to those without STBs (all <em>p</em>_<em>s</em> &lt; 0.001). The P3a latency predicted the general psychopathology scores (β = 0.103, <em>p</em> &lt; 0.001), and the N1 amplitude predicted the HAMD scores (β = −1.057, <em>p</em> = 0.001), both exclusively within the STBs group. Logistic regression analysis identified that N1 amplitude (Beta = −0.132, <em>p</em> = 0.018, OR = 1.02, 95%CI = 1.01–1.04) and HAMD scores (Beta = 0.068, <em>p</em> = 0.001, OR = 1.07, 95%CI = 1.03–1.11) as independent predictors of STBs in FEAN-SZ patients. Combining these variables yielded an area under the receiver operating characteristic (AUCROC) curve of 0.840 for distinguishing between patients with and without STBs.</div></div><div><h3>Conclusions</h3><div>FEAN-SZ patients with STBs have lower P3 amplitude and longer latency. The N1 amplitude and depressive levels are associated with STBs in FEAN-SZ patients. The N1 amplitude may serve as an early biological marker for STBs in SZ patients.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"274 ","pages":"Pages 352-359"},"PeriodicalIF":3.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142539005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional Mendelian randomization to explore the causal relationships between schizophrenia and narcolepsy","authors":"Chaofan Geng ,&nbsp;Chen Chen","doi":"10.1016/j.schres.2024.10.007","DOIUrl":"10.1016/j.schres.2024.10.007","url":null,"abstract":"<div><h3>Introduction</h3><div>This study employs the Mendelian Randomization (MR) approach to explore the potential causal relationship between schizophrenia and the risk of developing narcolepsy.</div></div><div><h3>Methods</h3><div>Genome-Wide Association Studies (GWAS) data from European populations were used to identify independent genetic variants associated with schizophrenia and narcolepsy, which were then used as instrumental variables in the analysis. The inverse variance weighting (IVW) method was performed to validate the findings. Effect sizes were presented as odds ratios (OR) and beta coefficients (β).</div></div><div><h3>Results</h3><div>The IVW analysis showed no significant causal relationship between schizophrenia and narcolepsy (OR: 1.002, 95 % CI: 0.996–1.007, <em>P</em> = 0.531). Likewise, the reverse analysis did not find any significant causal association (OR: 1.059, 95 % CI: 0.717–1.567, <em>P</em> = 0.421). Sensitivity analyses further confirmed the robustness of these findings.</div></div><div><h3>Conclusion</h3><div>The MR analysis does not provide evidence for a bidirectional causal relationship between schizophrenia and narcolepsy. Further research is needed to elucidate the underlying mechanisms and to identify potential targets for intervention.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"274 ","pages":"Pages 345-351"},"PeriodicalIF":3.6,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142507021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aberrant salience signaling in auditory processing in schizophrenia: Evidence for abnormalities in both sensory processing and emotional reactivity","authors":"Mahima Dewan ,&nbsp;Emily Campbell (Daniels) ,&nbsp;Jared E. Hunt ,&nbsp;Emily A. Bryant ,&nbsp;Samantha I. Trikeriotis ,&nbsp;Deanna L. Kelly ,&nbsp;Heather A. Adams ,&nbsp;Stephanie M. Hare ,&nbsp;James A. Waltz","doi":"10.1016/j.schres.2024.09.026","DOIUrl":"10.1016/j.schres.2024.09.026","url":null,"abstract":"<div><div>It has been long known that people with schizophrenia (SZ) have deficits in perceptual processing, including in the auditory domain. Furthermore, they often experience increased emotional responsivity and dysregulation, which further impacts overall functioning. Increased emotional responsivity to auditory stimuli is also seen in people with misophonia, a condition in which specific sounds elicit robust negative emotional responses. Given the role of emotional reactivity and dysregulation in the pathogenesis of SZ, our study investigated whether misophonia symptoms were elevated in SZ, or if people with SZ have a generalized increase in reactivity to sensory information. To explore the link between emotional reactivity to sound and more general aspects emotional reactivity and salience signaling in SZ, we used the Misophonia Questionnaire, the Sensory Processing Scale (SPS), and Aberrant Salience Inventory (ASI) in 30 people with SZ and 28 demographically-matched healthy volunteers (HVs). We found that people with SZ exhibited more emotional behavior associated with misophonia symptoms (specifically, distress in relation to sound) than HVs (t₅₆ = 4.889, <em>p</em> &lt; 0.001), but did not have elevated rates of misophonia overall. Also, sensory processing abnormalities and heightened emotional responses in people with SZ were not limited to the auditory domain but, rather, extended to all sensory modalities. Our results support the idea that SZ involves dysfunction in salience signaling, regarding auditory stimuli, but that abnormalities in salience signaling in SZ are more domain-general. These results highlight the importance of interventions designed to enhance emotion regulation in patients with SZ regarding stimuli in multiple modalities.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"274 ","pages":"Pages 329-336"},"PeriodicalIF":3.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142507018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic self-disturbance in schizophrenia: From neuronal to mental topographic dedifferentiation","authors":"Sami George Sabbah,&nbsp;Georg Northoff","doi":"10.1016/j.schres.2024.09.034","DOIUrl":"10.1016/j.schres.2024.09.034","url":null,"abstract":"","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"274 ","pages":"Pages 327-328"},"PeriodicalIF":3.6,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142507020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The COMPASS scale for the assessment of individuals with first episode psychotic disorders","authors":"Delbert G. Robinson ,&nbsp;Majnu John ,&nbsp;Alexander L. Miller ,&nbsp;Nina R. Schooler ,&nbsp;John M. Kane","doi":"10.1016/j.schres.2024.10.009","DOIUrl":"10.1016/j.schres.2024.10.009","url":null,"abstract":"<div><h3>Background</h3><div>Psychosis symptom assessment instruments are rarely used in US mental health community clinical practice despite the advantages of measurement-based care. Barriers include the length of typical scales and that data for scale evaluation often come from researcher and not clinician raters.</div></div><div><h3>Study design</h3><div>The 12-item COMPASS symptom assessment was designed for the RAISE-ETP study of early phase psychosis. Ratings were done by community facility clinicians. COMPASS psychometric properties were examined with a Mokken scale analysis. Subsequently, Mokken analyses were done on 10-item COMPASS data from the ESPRITO learning health system.</div></div><div><h3>Study results</h3><div>3600 RAISE-ETP COMPASS assessments were examined. The COMPASS 12-item version fulfilled Mokken scale criteria for unidimensionality (H = 0.329 (SE:0.007)) as did a derived reduced 10-item version (H = 0.359 (SE:0.007)) and 5-item version (H = 0.396 (SE = 0.009)). The 12-item version showed one significant monotonicity violation; no significant violations were found in the reduced item versions. Of the reduced item versions, clinicians preferred the 10-item over the 5-item version. In the ESPRITO data, both the 10-item and 5-item versions met unidimensionality criteria (H = 0.458 (SE:0.030) and 0.478 (0.034) respectively) with no monotonicity violations.</div></div><div><h3>Conclusions</h3><div>The COMPASS scale offers clinicians versions with varying lengths for assessment of individuals with first episode psychotic disorders in community settings. COMPASS can also facilitate data collection for large scale initiatives; the 10-item version is a symptom assessment option in the US national EPINET project.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"274 ","pages":"Pages 307-314"},"PeriodicalIF":3.6,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142507022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia","authors":"Daniela L. Uliana,&nbsp;Angela Martinez,&nbsp;Anthony A. Grace","doi":"10.1016/j.schres.2024.10.003","DOIUrl":"10.1016/j.schres.2024.10.003","url":null,"abstract":"<div><div>Schizophrenia (SCZ) is a complex neuropsychiatric disorder characterized by positive, negative, and cognitive symptoms. The neurodevelopmental methylazoxy-methanol acetate (MAM) rodent model replicates key neurobiological features of SCZ which includes hyperdopaminergic states in the ventral tegmental area (VTA) and cognitive deficits. Typical and atypical antipsychotics are primarily effective in treating the positive symptoms of SCZ but often fall short of addressing cognitive deficits. A promising therapeutic approach for treating all symptoms of SCZ has emerged through the inhibition of phosphodiesterase 10 A (PDE10A). Our study aim was to investigate the impact of acute and chronic THPP-1 (PDE10A inhibitor) treatment, in MAM rats, focusing on cognitive deficits and VTA dopamine (DA) activity. Adult offspring of pregnant rats treated with Saline or MAM (20 mg/kg) on gestational day 17 were treated with THPP-1 acutely (male/female rats; 3 mg/kg) at postnatal day (PD) 70–80 or chronically (males; 3 weeks; 2-3 mg/kg) from PD 70–91 and tested in the novel object recognition test and electrophysiological recording of DA neurons in the VTA. Acute THPP-1 treatment reversed cognitive impairments and normalized the increased number of active DA neurons in the VTA of male and female MAM rats, without affecting control rats. Also, chronic THPP-1 treatment reversed cognitive deficits and normalized DA hyperactivity in the VTA of male MAM rats. The efficacy of THPP-1 in reversing MAM-induced impairments underscores its ability to target disease-specific circuitry without affecting normal regulated systems in control rats. Our findings highlight the therapeutic potential of THPP-1 for addressing cognitive deficits and DA dysregulation in SCZ.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"274 ","pages":"Pages 315-326"},"PeriodicalIF":3.6,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142507023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients","authors":"Franciska de Beer ,&nbsp;Ben Wijnen ,&nbsp;Lotte Wouda ,&nbsp;Sanne Koops ,&nbsp;Shiral Gangadin ,&nbsp;Wim Veling ,&nbsp;Nico van Beveren ,&nbsp;Lieuwe de Haan ,&nbsp;Marieke J.H. Begemann ,&nbsp;HAMLETT-OPHELIA consortium,&nbsp;Iris E.C. Sommer","doi":"10.1016/j.schres.2024.09.030","DOIUrl":"10.1016/j.schres.2024.09.030","url":null,"abstract":"<div><div>Negative symptoms can be an integral part of schizophrenia spectrum pathology and can be secondary to other psychotic symptoms or caused by antipsychotic medication. As antipsychotic drugs differ in their affinity to dopamine receptors and some antipsychotics have partial agonistic effects, antipsychotic drugs are expected to vary in their ability to cause negative symptoms.</div><div>The association between negative symptoms and antipsychotic medication divided into partial agonists, or antagonists with high or low D₂ affinity was assessed in 310 remitted first episode psychosis (FEP) patients. Severity of negative symptoms was assessed with the Comprehensive Assessment of Symptoms and History, and the Positive and Negative Syndrome Scale. Linear regression analyses were performed while controlling for differences in clinical and sociodemographic characteristics between the groups using inverse probability of treatment weighting.</div><div>Patients using partial agonists (<em>n</em> = 78) showed fewer negative symptoms compared to those using high affinity antagonists (<em>n</em> = 84). Patients using partial agonists displayed less severe negative symptoms compared to those using low affinity antagonists (<em>n</em> = 148) at a trend level (<em>p</em> = 0.051). Negative symptom severity was higher in patients who had higher antipsychotic doses.</div><div>In remitted FEP patients, we observed that the use of antipsychotic medication classified as partial agonists was associated with lower severity of negative symptoms, while the use of antagonists with high D₂ affinity was associated with more severe negative symptoms.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"274 ","pages":"Pages 299-306"},"PeriodicalIF":3.6,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}